Tuberculosis Infection

Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a retrospective study.

Although the United States has one of the lowest tuberculosis incidence rates in the world, TB cases increased in the U.S. in 2023 among nearly all demographics, data from an MMWR report showed.

Researchers linked more than 1 million deaths in Africa in 2019 to antimicrobial resistance, more than half of which were linked to just four pathogens.

Many patients with tuberculosis who were potentially eligible for a shorter 4-month therapy were treated with standard 6-month courses, according to a recent study.

People with hepatitis C, either treated or untreated, had an increased risk for developing active tuberculosis, according to data published in Clinical Infectious Diseases.

Disruptions to care caused by the COVID-19 pandemic continued to negatively impact the fight against tuberculosis as cases and deaths have increased for the second year in a row after decades of declines, according to WHO’s 2022 Global TB Report.

According to a new report, global funding for tuberculosis research totaled $915 million in 2020 — less than half of the $2 billion goal set at the 2018 United Nations High-Level Meeting on TB.

A 4-month daily regimen of rifapentine and moxifloxacin was noninferior to the standard 6-month regimen for tuberculosis treatment among people with HIV enrolled in a phase 3 clinical trial, researchers reported at CROI.